Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

120
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
120
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

160
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
160
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

362
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
362
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

215
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
215
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

276
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
276
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

129
In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
129

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sodium load of novel antibiotics: considerations for nephrologists and clinicians.

International urology and nephrology·2025
Same author

Cardiac complications in autosomal dominant polycystic kidney disease: links to genotype and CKD severity.

Clinical kidney journal·2025
Same author

A novel CT-based radiomics approach for kidney function evaluation in ADPKD: a pilot study.

Clinical kidney journal·2025
Same author

Prescription of ACE-Is/ARBs in patients with cardio-renal disease: a multicenter retrospective cohort study from the REPOSI registry.

Internal and emergency medicine·2025
Same author

Potential Add-On Benefits of Dietary Intervention in the Treatment of Autosomal Dominant Polycystic Kidney Disease.

Nutrients·2024
Same author

Impact of the COVID-19 pandemic on the Italian national viral hepatitis surveillance: an interrupted time series analysis, 2006-2022.

Public health·2024

Related Experiment Video

Updated: Dec 26, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.9K

Renal Volume in ADPKD Patient Evaluation.

M Galliani1, E Vitaliano1, S Chicca1

  • 1UOC Nefrologia, Dialisi e Litotrissia, Ospedale Sandro Pertini, Roma, Italy.

International Journal of Nephrology
|March 12, 2020
PubMed
Summary

The Mayo Clinic classification effectively identifies Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients at risk of rapid progression. This method aids in predicting complications and eligibility for treatments like Tolvaptan.

More Related Videos

Use of 3D Robotic Ultrasound for In Vivo Analysis of Mouse Kidneys
08:21

Use of 3D Robotic Ultrasound for In Vivo Analysis of Mouse Kidneys

Published on: August 12, 2021

3.9K
Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography
03:19

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography

Published on: June 21, 2024

2.0K

Related Experiment Videos

Last Updated: Dec 26, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.9K
Use of 3D Robotic Ultrasound for In Vivo Analysis of Mouse Kidneys
08:21

Use of 3D Robotic Ultrasound for In Vivo Analysis of Mouse Kidneys

Published on: August 12, 2021

3.9K
Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography
03:19

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography

Published on: June 21, 2024

2.0K

Area of Science:

  • Nephrology
  • Medical Imaging
  • Genetics

Background:

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD) clinical manifestations stem from renal cyst growth.
  • Renal volume is a key biomarker for predicting complications such as hypertension, hematuria, and progression to End-Stage Renal Disease (ESRD).
  • Existing scores for predicting ADPKD evolution require further validation.

Purpose of the Study:

  • To evaluate the utility of the Mayo Clinic classification system in predicting ADPKD progression.
  • To assess the correlation between renal volume, hypertension, and GFR in ADPKD patients.
  • To determine the eligibility of ADPKD patients for Tolvaptan therapy based on the Mayo classification.

Main Methods:

  • Retrospective study of 80 patients with typical ADPKD (Mayo class 1A-1E).
  • Patients underwent MRI for renal volume measurement (Ht-TKV).
  • Correlation analysis between renal volume, hypertension, GFR, and Mayo class.

Main Results:

  • A significant correlation was observed between increased renal volume, hypertension, and reduced Glomerular Filtration Rate (GFR) (p < 0.005).
  • Disease severity progressively increased across different Mayo classes.
  • 41.2% of the studied patients were identified as eligible for Tolvaptan therapy.

Conclusions:

  • The Mayo Clinic classification method is straightforward and provides valuable information for identifying rapidly progressing ADPKD.
  • This classification aids in risk stratification and informs treatment decisions, including eligibility for Tolvaptan.
  • Renal volume measurement is a crucial tool in managing ADPKD patients.